FDA approves trimetrexate as second-line therapy for Pneumocystis carinii pneumonia.
D006801:Humans; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy*; D016597:Trimetrexate / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D016597:Trimetrexate